These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7519507)

  • 1. The expression of FMS, KIT and FLT3 in hematopoietic malignancies.
    Birg F; Rosnet O; Carbuccia N; Birnbaum D
    Leuk Lymphoma; 1994 Apr; 13(3-4):223-7. PubMed ID: 7519507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic receptors of class III receptor-type tyrosine kinases.
    Rosnet O; Birnbaum D
    Crit Rev Oncog; 1993; 4(6):595-613. PubMed ID: 7506935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.
    Carow CE; Levenstein M; Kaufmann SH; Chen J; Amin S; Rockwell P; Witte L; Borowitz MJ; Civin CI; Small D
    Blood; 1996 Feb; 87(3):1089-96. PubMed ID: 8562934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor.
    Lyman SD; Brasel K; Rousseau AM; Williams DE
    Stem Cells; 1994; 12 Suppl 1():99-107; discussion 108-10. PubMed ID: 7535149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor beta 1 inhibits expression of the gene products for steel factor and its receptor (c-kit).
    Heinrich MC; Dooley DC; Keeble WW
    Blood; 1995 Apr; 85(7):1769-80. PubMed ID: 7535588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells.
    Ratajczak MZ; Kuczynski WI; Sokol DL; Moore JS; Pletcher CH; Gewirtz AM
    Blood; 1995 Sep; 86(6):2161-7. PubMed ID: 7545021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment.
    Gattei V; Celetti A; Cerrato A; Degan M; De Iuliis A; Rossi FM; Chiappetta G; Consales C; Improta S; Zagonel V; Aldinucci D; Agosti V; Santoro M; Vecchio G; Pinto A; Grieco M
    Blood; 1997 Apr; 89(8):2925-37. PubMed ID: 9108413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fms-like tyrosine kinase 3 catalytic domain can transduce a proliferative signal in FDC-P1 cells that is qualitatively similar to the signal delivered by c-Fms.
    Rossner MT; McArthur GA; Allen JD; Metcalf D
    Cell Growth Differ; 1994 May; 5(5):549-55. PubMed ID: 8049161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
    Rosnet O; Bühring HJ; Marchetto S; Rappold I; Lavagna C; Sainty D; Arnoulet C; Chabannon C; Kanz L; Hannum C; Birnbaum D
    Leukemia; 1996 Feb; 10(2):238-48. PubMed ID: 8637232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts.
    Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W
    Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.
    Rosnet O; Schiff C; Pébusque MJ; Marchetto S; Tonnelle C; Toiron Y; Birg F; Birnbaum D
    Blood; 1993 Aug; 82(4):1110-9. PubMed ID: 8394751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
    Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3 tyrosine kinase as a target in acute leukemias.
    Griffin JD
    Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular genetic approaches to the elucidation of hematopoietic stem cell function.
    Bernstein A
    Stem Cells; 1993 Jul; 11 Suppl 2():31-5. PubMed ID: 7691325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexpression of the c-kit and stem cell factor genes in breast carcinomas.
    Hines SJ; Organ C; Kornstein MJ; Krystal GW
    Cell Growth Differ; 1995 Jun; 6(6):769-79. PubMed ID: 7545433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of cytokine receptors by purified hemopoietic stem cells.
    Visser JW; Rozemuller H; de Jong MO; Belyavsky A
    Stem Cells; 1993 Jul; 11 Suppl 2():49-55. PubMed ID: 7691328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of flt3 ligand and receptor.
    Lyman SD
    Int J Hematol; 1995 Aug; 62(2):63-73. PubMed ID: 8590775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells.
    Lyman SD; James L; Vanden Bos T; de Vries P; Brasel K; Gliniak B; Hollingsworth LT; Picha KS; McKenna HJ; Splett RR
    Cell; 1993 Dec; 75(6):1157-67. PubMed ID: 7505204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue.
    Strohmeyer T; Reese D; Press M; Ackermann R; Hartmann M; Slamon D
    J Urol; 1995 Feb; 153(2):511-5. PubMed ID: 7529338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.